Vistagen's fasedienol shows positive data in open-label extension for social anxiety disorder

Vistagen's open-label extension of its PALISADE-4 Phase 3 trial for fasedienol in social anxiety disorder shows positive data, despite the double-blind portion missing its primary endpoint. The extension data could inform durability and tolerability but does not confirm efficacy, leaving Vistagen to consider new regulatory or development strategies.

This Wire brief sits within Fusion42's coverage of Drug Discovery.